GH Research Group (GHRS) - מקדם חוב לטווח ארוך להון

GH Research PLC (GHRS) aims to capture the antidepressant market via its inhalable drug GH001, which is currently in the final stage of testing. The price action on the GURU.Markets chart, where the indicator stands at 0.00, confirms the company's strong position driven by patents for psychedelic therapy. Business growth relies on the success of 5-MeO-DMT trials and the increasing demand for modern methods to treat severe mental health conditions.

The specific nature of GH Research PLC (GHRS), a biotech firm focused on organic trials without M&A, is clearly reflected in the long-term debt-to-equity chart. This indicator compares liabilities with maturities exceeding one year against the issuer's equity, allowing for an assessment of financial stability and the balance between capital security and the efficient use of leverage for growth.